Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653432 | 0.93 | SIRT5 (0.51) | SIRT5KCNA5PTGER4HDAC1HDAC2 | |
| SCHEMBL5654083 | 0.89 | CA1 (0.52) | SIRT5PTGER4SIRT1SIRT2CA1 | |
| SCHEMBL5740585 | 0.85 | CA1 (0.50) | SIRT5PTGER4SIRT1SIRT2CA1 | |
| SCHEMBL5655221 | 0.85 | FAP (0.47) | SIRT5PTGER4SIRT1SIRT2CA1 | |
| SCHEMBL5653306 | 0.85 | SIRT5 (0.42) | SIRT5PTGER4SIRT1SIRT2CA1 | |
| SCHEMBL5653258 | 0.85 | KLK7 (0.51) | SIRT5SIRT1SIRT2 | |
| SCHEMBL5653753 | 0.84 | NR1H4 (0.49) | SIRT5PTGER4SIRT1SIRT2CA1 | |
| SCHEMBL5654264 | 0.84 | CA1 (0.47) | SIRT5PTGER4SIRT1SIRT2CA1 | |
| SCHEMBL5739335 | 0.84 | PTGER4 (0.44) | SIRT5PTGER4SIRT1SIRT2CA1 | |
| SCHEMBL5654879 | 0.83 | HDAC1 (0.49) | SIRT5PTGER4SIRT1SIRT2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | ASTELLAS PHARMA INC. (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1697337-A2 | ORNITHINE DERIVATIVES AS PROSTAGLANDIN-E2-AGONISTS OR ANTAGONISTS | Astellas Pharma Inc. (JP) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061475-A2 | ORNITHINE DERIVATIVES AS PROSTAGLANDIN E2 AGONISTS OR ANTAGONISTS | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | PTGER4, OXER1, RXFP4 | SIRT5 1504/4885KCNA5 1149/4885PTGER4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.